Effective interventions for potentially modifiable risk factors for late-onset dementia: a costs and cost-effectiveness modelling study.


Journal

The lancet. Healthy longevity
ISSN: 2666-7568
Titre abrégé: Lancet Healthy Longev
Pays: England
ID NLM: 101773309

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 07 07 2020
revised: 14 07 2020
accepted: 15 07 2020
entrez: 12 9 2022
pubmed: 1 10 2020
medline: 1 10 2020
Statut: ppublish

Résumé

The potential economic value of interventions to prevent late-onset dementia is unknown. We modelled this for potentially modifiable risk factors for dementia. For this modelling study, we searched PubMed and Web of Science from inception to March 12, 2020, and included interventions that: successfully targeted any of nine prespecified potentially modifiable risk factors (hypertension, diabetes, hearing loss, obesity, physical inactivity, social isolation, depression, cigarette smoking, and less childhood education); had robust evidence that the intervention improved risk or risk behaviour; and are feasible to enact in an adult population. We established when in the life course each intervention would be delivered. We calculated dementia incidence reduction from annual incidence of dementia in people with each risk factor, and population attributable fraction for each risk, corrected for risk factor clustering, and how effectively the intervention controls the risk factor. We calculated the discounted value of lifetime health gain and effect on cost (including NHS, social care and carer costs) per person eligible for treatment. We estimated annual total expenditure on the fully operational intervention programme in England. We found effective interventions for hypertension, smoking cessation, diabetes prevention, and hearing loss. Treatments for stopping smoking and provision of hearing aids reduced cost. Treatment of hypertension was cost-effective by reference to standard UK thresholds. The three interventions when fully implemented would save £1·863 billion annually in England, reduce dementia prevalence by 8·5%, and produce quality-adjusted life-year gains. The intervention for diabetes was unlikely to be cost-effective in terms of effect on dementia alone. There is a strong case for implementing the three effective interventions on grounds of cost-effectiveness and quality-of-life gains, as well as for improvements in general health. The interventions have the potential to remain cost-saving or cost-effective even with variations in dementia incidence and costs and effectiveness of interventions. Economic and Social Research Council.

Sections du résumé

BACKGROUND BACKGROUND
The potential economic value of interventions to prevent late-onset dementia is unknown. We modelled this for potentially modifiable risk factors for dementia.
METHODS METHODS
For this modelling study, we searched PubMed and Web of Science from inception to March 12, 2020, and included interventions that: successfully targeted any of nine prespecified potentially modifiable risk factors (hypertension, diabetes, hearing loss, obesity, physical inactivity, social isolation, depression, cigarette smoking, and less childhood education); had robust evidence that the intervention improved risk or risk behaviour; and are feasible to enact in an adult population. We established when in the life course each intervention would be delivered. We calculated dementia incidence reduction from annual incidence of dementia in people with each risk factor, and population attributable fraction for each risk, corrected for risk factor clustering, and how effectively the intervention controls the risk factor. We calculated the discounted value of lifetime health gain and effect on cost (including NHS, social care and carer costs) per person eligible for treatment. We estimated annual total expenditure on the fully operational intervention programme in England.
FINDINGS RESULTS
We found effective interventions for hypertension, smoking cessation, diabetes prevention, and hearing loss. Treatments for stopping smoking and provision of hearing aids reduced cost. Treatment of hypertension was cost-effective by reference to standard UK thresholds. The three interventions when fully implemented would save £1·863 billion annually in England, reduce dementia prevalence by 8·5%, and produce quality-adjusted life-year gains. The intervention for diabetes was unlikely to be cost-effective in terms of effect on dementia alone.
INTERPRETATION CONCLUSIONS
There is a strong case for implementing the three effective interventions on grounds of cost-effectiveness and quality-of-life gains, as well as for improvements in general health. The interventions have the potential to remain cost-saving or cost-effective even with variations in dementia incidence and costs and effectiveness of interventions.
FUNDING BACKGROUND
Economic and Social Research Council.

Identifiants

pubmed: 36094185
pii: S2666-7568(20)30004-0
doi: 10.1016/S2666-7568(20)30004-0
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13-e20

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Naaheed Mukadam (N)

Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK. Electronic address: n.mukadam@ucl.ac.uk.

Robert Anderson (R)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.

Martin Knapp (M)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.

Raphael Wittenberg (R)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.

Maria Karagiannidou (M)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.

Sergi G Costafreda (SG)

Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.

Madison Tutton (M)

Division of Psychiatry, University College London, London, UK.

Charles Alessi (C)

Public Health England, London, UK.

Gill Livingston (G)

Division of Psychiatry, University College London, London, UK; Camden and Islington NHS Foundation Trust, London, UK.

Classifications MeSH